Key Takeaways
- • Healthcare IT has delivered superior investment returns versus other healthcare subsectors since 2017, with deal volumes increasing to nearly 20% of healthcare transactions in 2025 from 15% in 2021, demonstrating sustained PE investor confidence despite macroeconomic volatility.
- • Winning healthcare IT investments achieve Rule of 60 outcomes through disciplined execution across three primary levers: pricing and packaging optimization, cross-selling expansion, and AI-enabled growth coupled with margin enhancement—moving beyond end-user adoption as the sole return driver.
- • Consistent, disciplined value-creation focus from underwriting through exit distinguishes highest-returning deals, with leading investors emphasizing differentiated assets, scale, revenue visibility, and selective platform-plus-tuck-in acquisition strategies.
- • Flagship 2025 transactions include Warburg Pincus selling a majority stake in ModMed (specialty EMR provider) to Clearlake Capital and Bain Capital, Bain Capital acquiring HealthEdge from Blackstone and merging it with HealthProof (payer IT), and Bain Capital's investment in Softway Medical Group (France-based health information system and EMR provider).
- • Generative AI presents dual opportunity and risk: top- and bottom-line value creation potential for healthcare IT providers alongside downside risks requiring careful navigation during platform development and integration.
Summary
Healthcare IT has solidified its position as a top-performing segment within private equity investment, consistently outpacing broader healthcare subsectors and most other industries since 2017. This sustained outperformance has driven increased capital deployment, with deal volumes surging to represent nearly 20% of all healthcare transactions in 2025—up from 15% in 2021. According to Bain's 2026 Global Healthcare Private Equity Report, this trajectory reflects strong underlying fundamentals in healthcare IT that have proven resilient across varying macroeconomic conditions.
The competitive landscape shifted markedly in 2025, characterized by large-scale, tailored systems-of-record transactions spanning payers, providers, and life sciences platforms. Major transactions underscore the scale and strategic importance of the subsector: Warburg Pincus divested a majority interest in ModMed, a specialty-focused electronic medical records provider, to Clearlake Capital; Bain Capital acquired HealthEdge from Blackstone and executed a merger with HealthProof to create an integrated payer IT platform; and Bain Capital invested in Softway Medical Group, a France-based health information system and EMR provider, signaling cross-border consolidation activity.
Bain's analysis reveals that leading investors distinguish themselves through execution discipline across specific value-creation levers rather than reliance on organic end-user adoption alone. The highest-returning deals achieve Rule of 60 outcomes—a benchmark metric indicating strong unit economics and growth efficiency—via three primary mechanisms: (1) pricing and packaging optimization to capture value from existing customer bases; (2) cross-selling expansion to penetrate adjacent use cases within installed customer accounts; and (3) AI-enabled growth and margin expansion that leverages generative AI to enhance both revenue and profitability. This multi-lever approach reflects a maturation in the subsector, where investors increasingly focus on operational leverage and platform extensibility.
Generative AI emerges as a critical value-creation driver and risk factor simultaneously. For healthcare IT providers, AI applications offer meaningful top-line revenue acceleration and bottom-line margin expansion opportunities. However, investors must actively navigate potential downside risks inherent in AI integration, including technology adoption risk, competitive displacement, and regulatory uncertainty. Bain's findings emphasize that consistent, disciplined focus on value creation—maintained rigorously from initial underwriting through final exit—remains the defining characteristic separating winning deals from underperforming investments in this increasingly competitive subsector.
The competitive landscape shifted markedly in 2025, characterized by large-scale, tailored systems-of-record transactions spanning payers, providers, and life sciences platforms. Major transactions underscore the scale and strategic importance of the subsector: Warburg Pincus divested a majority interest in ModMed, a specialty-focused electronic medical records provider, to Clearlake Capital; Bain Capital acquired HealthEdge from Blackstone and executed a merger with HealthProof to create an integrated payer IT platform; and Bain Capital invested in Softway Medical Group, a France-based health information system and EMR provider, signaling cross-border consolidation activity.
Bain's analysis reveals that leading investors distinguish themselves through execution discipline across specific value-creation levers rather than reliance on organic end-user adoption alone. The highest-returning deals achieve Rule of 60 outcomes—a benchmark metric indicating strong unit economics and growth efficiency—via three primary mechanisms: (1) pricing and packaging optimization to capture value from existing customer bases; (2) cross-selling expansion to penetrate adjacent use cases within installed customer accounts; and (3) AI-enabled growth and margin expansion that leverages generative AI to enhance both revenue and profitability. This multi-lever approach reflects a maturation in the subsector, where investors increasingly focus on operational leverage and platform extensibility.
Generative AI emerges as a critical value-creation driver and risk factor simultaneously. For healthcare IT providers, AI applications offer meaningful top-line revenue acceleration and bottom-line margin expansion opportunities. However, investors must actively navigate potential downside risks inherent in AI integration, including technology adoption risk, competitive displacement, and regulatory uncertainty. Bain's findings emphasize that consistent, disciplined focus on value creation—maintained rigorously from initial underwriting through final exit—remains the defining characteristic separating winning deals from underperforming investments in this increasingly competitive subsector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.